Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Acne Conglobata
NCT04161456Phase 2Completed
- Sponsor
- Dr. Frank Behrens
- Start
- Oct 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apremilast in acne conglobata (AC), sponsored by Dr. Frank Behrens. Primary endpoint: 50% reduction in number of lesion at 24 weeks. Started Oct 2019; status: completed.
02
Drugs
apremilast
03
Conditions
acne conglobata (AC)
Beyond the preview
Go deeper on NCT04161456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04161456.